Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645932 | 0.76 | HTR7 (0.45) | HTR7ADORA2AADORA1USP30USP7 | |
| SCHEMBL14791433 | 0.70 | KCNK3 (0.55) | LRRK2MAPK1KCNK3ADORA2AUSP30 | |
| SCHEMBL19358368 | 0.69 | USP7 (0.73) | LRRK2HTR7ADORA2AADORA2BADORA1 | |
| SCHEMBL11628346 | 0.66 | GSK3A (0.58) | LRRK2PIN1GRK6PGRADORA2A | |
| SCHEMBL17868167 | 0.64 | LMNA (0.50) | HTR7CREBBPUSP7 | |
| SCHEMBL23329264 | 0.64 | HAO1 (0.49) | PIN1GRK6ADORA2AADORA1 | |
| SCHEMBL5271713 | 0.63 | IDO1 (0.46) | LRRK2PIN1PGRADORA2AADORA2B | |
| SCHEMBL11629148 | 0.63 | GSK3A (0.46) | LRRK2GRK6PGRADORA2AADORA2B | |
| SCHEMBL23998166 | 0.63 | ADORA2A (0.58) | ADORA2AADORA2BADORA1IDO1MAOB | |
| SCHEMBL17696918 | 0.63 | AURKA (0.60) | LRRK2MAPK1ADORA2AADORA1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598410-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | KCNA1, KCNT1, CACNA1I | LRRK2 2660/4885MAPK1 388/4885PIN1 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.